Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Revenue (2020 - 2025)

Historic Revenue for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to $132000.0.

  • Ovid Therapeutics' Revenue fell 2369.94% to $132000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year decrease of 9707.38%. This contributed to the annual value of $566000.0 for FY2024, which is 4438.78% up from last year.
  • Ovid Therapeutics' Revenue amounted to $132000.0 in Q3 2025, which was down 2369.94% from $6.3 million recorded in Q2 2025.
  • In the past 5 years, Ovid Therapeutics' Revenue ranged from a high of $222.8 million in Q4 2023 and a low of $11102.0 during Q3 2022
  • Its 5-year average for Revenue is $58.9 million, with a median of $169000.0 in 2024.
  • In the last 5 years, Ovid Therapeutics' Revenue soared by 377502.64% in 2021 and then plummeted by 9956.81% in 2022.
  • Ovid Therapeutics' Revenue (Quarter) stood at $221.0 million in 2021, then grew by 0.68% to $222.5 million in 2022, then rose by 0.13% to $222.8 million in 2023, then tumbled by 99.92% to $173000.0 in 2024, then decreased by 23.7% to $132000.0 in 2025.
  • Its Revenue stands at $132000.0 for Q3 2025, versus $6.3 million for Q2 2025 and $130000.0 for Q1 2025.